Zur Kurzanzeige

2020-03-04Zeitschriftenartikel DOI: 10.25646/6906
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators
dc.contributor.authorHeppt, Markus V.
dc.contributor.authorLeiter, Ulrike
dc.contributor.authorSteeb, Theresa
dc.contributor.authorAmaral, Teresa
dc.contributor.authorBauer, Andrea
dc.contributor.authorBecker, Jürgen C.
dc.contributor.authorBreitbart, Eckhard
dc.contributor.authorBreuninger, Helmut
dc.contributor.authorDiepgen, Thomas
dc.contributor.authorDirschka, Thomas
dc.contributor.authorEigentler, Thomas
dc.contributor.authorFlaig, Michael
dc.contributor.authorFollmann, Markus
dc.contributor.authorFritz, Klaus
dc.contributor.authorGreinert, Rüdiger
dc.contributor.authorGutzmer, Ralf
dc.contributor.authorHillen, Uwe
dc.contributor.authorIhrler, Stephan
dc.contributor.authorJohn, Swen Malte
dc.contributor.authorKölbl, Oliver
dc.contributor.authorKraywinkel, Klaus
dc.contributor.authorLöser, Christoph
dc.contributor.authorNashan, Dorothée
dc.contributor.authorNoor, Seema
dc.contributor.authorNothacker, Monika
dc.contributor.authorPfannenberg, Christina
dc.contributor.authorSalavastru, Carmen
dc.contributor.authorSchmitz, Lutz
dc.contributor.authorStockfleth, Eggert
dc.contributor.authorSzeimies, Rolf-Markus
dc.contributor.authorUlrich, Claas
dc.contributor.authorWelzel, Julia
dc.contributor.authorWermker, Kai
dc.contributor.authorBerking, Carola
dc.contributor.authorGarbe, Claus
dc.date.accessioned2020-05-26T12:02:58Z
dc.date.available2020-05-26T12:02:58Z
dc.date.issued2020-03-04none
dc.identifier.other10.1111/ddg.14048
dc.identifier.urihttp://edoc.rki.de/176904/6794
dc.description.abstractActinic keratoses (AK) are common lesions in light‐skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence‐based framework for clinical decision making, the guideline “actinic keratosis and cutaneous squamous cell carcinoma” was developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guideline is aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office‐based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AK and cSCC. The guideline is also aimed at affected patients, their relatives, policy makers and insurance funds. In the first part, we will address aspects relating to diagnosis, interventions for AK, care structures and quality‐of‐care indicators.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleS3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicatorsnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6794-6
dc.identifier.doihttp://dx.doi.org/10.25646/6906
dc.type.versionpublishedVersionnone
local.edoc.container-titleJDDG: Journal der Deutschen Dermatologischen Gesellschaftnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14048none
local.edoc.container-publisher-nameWiley Blackwellnone
local.edoc.container-volume18none
local.edoc.container-issue3none
local.edoc.container-year2020none
local.edoc.container-firstpage275none
local.edoc.container-lastpage293none
local.edoc.rki-departmentInfektionsepidemiologienone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige